OM
CNTX icon

Opaleye Management’s Context Therapeutics CNTX Stock Holding History

Opaleye Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,108,357
Closed -$1.53M – 53
2024
Q1 		$1.53M Buy
1,108,357
+133,357
+14% +$150K 0.33% 42
2023
Q4 		$1.1M Buy
+975,000
New +$1.05M 0.29% 43

Other funds holding CNTX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Opaleye Management's CNTX Position: Q2 2024 in Review

Opaleye Management sold out of Context Therapeutics (CNTX) in Q2 2024, closing a stake of 1,108,357 shares — an estimated $1.53M sold.

Opaleye Management first reported a position in CNTX in Q4 2023 and held it in 2 quarters. The position peaked at $1.53M in Q1 2024. 34 funds tracked by Wall St. Rank hold CNTX as of Q2 2024.

  • Opaleye Management reported no remaining Context Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Opaleye Management sold 1,108,357 Context Therapeutics shares in Q2 2024, an estimated $1.53M.
  • Opaleye Management first reported a position in Context Therapeutics in Q4 2023 and held it in 2 quarters.
  • Opaleye Management's Context Therapeutics position peaked at $1.53M in Q1 2024.
  • 34 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2024.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.